Table 1. Clinical data of included patients (n = 155).
| Variable | N (%) | Median (minimum– maximum)/mean (± SD) |
|---|---|---|
| Time to metastasis | 155 (100) | 61.87 months (7.00–184.80) |
| Time to progression | 155 (100) | 60.07 months (7.00–184.80) |
| Time to death | 155 (100) | 65.83 months (7.00–184.80) |
| Time to end of adjuvance | 155 (100) | 16.93 months (1.40–53.40) |
| Age | 155 (100) | 53 years (28–79) |
| Age | ||
| <70 years | 146 (94.2) | |
| ≥70 years | 9 (5.8) | |
| Distant metastasis developed | ||
| No | 126 (81.3) | |
| Yes | 29 (18.7) | |
| Progression | ||
| No | 119 (76.8) | |
| Yes | 36 (23.20) | |
| Deaths | ||
| No | 128 (82.6) | |
| Yes | 27 (17.4) | |
| T (initial) | ||
| T1 | 37 (23.9) | |
| T2 | 63 (40.6) | |
| T3 | 30 (19.4) | |
| T4 | 25 (16.1) | |
| N (initial) | ||
| N0 | 68 (43.9) | |
| N1 | 48 (31.0) | |
| N2 | 26 (16.8) | |
| N3 | 13 (8.4) | |
| T (pathological) | ||
| T1 | 55 (35.5) | |
| T2 | 77 (49.7) | |
| T3 | 13 (8.4) | |
| T4 | 10 (6.5) | |
| N (pathological) | ||
| N0 | 84 (54.2) | |
| N1 | 38 (24.5) | |
| N2 | 23 (14.8) | |
| N3 | 10 (6.5) | |
| Histological grade | ||
| G1 | 6 (3.9) | |
| G2 | 106 (68.4) | |
| G3 | 43 (27.7) | |
| Hormone receptor | ||
| Negative | 64 (41.3) | |
| Positive | 91 (58.7) | |
| Trastuzumab (any quantity) | ||
| Did not received | 59 (38.1) | |
| Received | 96 (61.9) | 365 days (21–502) |
| Trastuzumab (63 days) | ||
| ≤63 days | 3 (3.1) | 63 days (21–63) |
| >63 days | 93 (96.9) | 365 days (71–502) |
| Trastuzumab (12 weeks) | ||
| ≤12 weeks | 5 (5.2) | 63 days (21–82) |
| >12 weeks | 91 (94.89) | 365 days (126–502) |
| Trastuzumab (6 months) | ||
| <6 months | 10 (10.4) | 104 days (21–169) |
| ≥6 months | 86 (89.6) | 367 days (216–502) |
| Trastuzumab (292 days) | ||
| ≤292 days | 59 (38.1) | 142.5 days (21–292) |
| >292 days | 96 (61.9) | 369 days (296–502) |
| Endocrine therapy | ||
| Negative | 8/91 (8.8) | |
| Positive | 83/91 (91.2) | |
| Chemotherapy | ||
| No | 10 (6.5) | |
| Neoadjuvant | 50 (32.3) | |
| Adjuvant | 95 (61.2) | |
| Systemic treatment (St. Gallen) | ||
| Inadequate | 85 (54.8) | |
| Adequate | 70 (45.2) | |
| Locoregional treatment | ||
| Inadequate | 14 (9.0) | |
| Adequate | 141 (91.0) |
G1, Well differentiated; G2, Moderately differentiated; G3, Poorly differentiated; N, Lymph node metastasis; T, Tumour size